[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity

Rhea-AI Filing Summary

Todd Berard, Chief Marketing Officer of BioLife Solutions, reported a sale of company stock on 09/11/2025. The Form 4 shows he disposed of 358 shares of common stock at a price of $26.83 per share under a Rule 10b5-1 trading plan adopted 03/08/2024 to satisfy tax withholding obligations tied to the vesting of restricted stock. After the transaction, Mr. Berard beneficially owned 133,906 shares directly. The filing is signed and dated 09/15/2025.

Positive

• Sale executed under a Rule 10b5-1(c) trading plan, indicating pre-established terms and reduced likelihood of opportunistic timing
• Clear disclosure of purpose: the sale was to satisfy tax withholding obligations related to restricted stock vesting
• Substantial retained ownership: reporting person still holds 133,906 shares directly after the sale

Negative

• Insider disposed of shares (358 shares), which investors may note as a sale by a company officer

Insights

Corporate Governance Specialist

Routine insider sale executed under a pre-established 10b5-1 plan to meet tax obligations; governance and timing reduce sign of opportunistic trading.

The sale is explicitly documented as executed under a Rule 10b5-1(c) plan adopted 03-08-2024 to satisfy tax withholding on restricted stock vesting. Use of a 10b5-1 plan indicates the trade was pre-planned and not an ad-hoc decision based on material nonpublic information. The reporting shows a modest disposition of 358 shares at $26.83 and a remaining direct beneficial ownership of 133,906 shares, which preserves continued ownership alignment.

Securities Analyst

Insider disposition is small and clearly disclosed; impacts on investor valuation are likely negligible based on the data in the filing.

The transaction is a non-derivative sale recorded on 09-11-2025 with proceeds implied by the per-share price of $26.83. The filing includes the mandated explanation that the sale satisfied tax withholding for vesting restricted stock. No additional transactions, derivative activity, or joint filers are reported. Based solely on this Form 4 content, the event appears routine and informational for market transparency.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Berard Todd

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		S(1)		358	D	$26.83	133,906	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Todd Berard	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BIOLIFE SOLUTIONS INC (BLFS) insider Todd Berard report on Form 4?

The Form 4 reports that Todd Berard, Chief Marketing Officer, sold 358 shares of BLFS common stock on 09/11/2025 at $26.83 per share.

Why were the shares sold according to the Form 4 for BLFS?

The filing states the sale was made pursuant to a Rule 10b5-1(c) trading plan adopted 03-08-2024 to satisfy tax withholding obligations arising from the vesting of restricted stock.

How many BLFS shares does Todd Berard own after the reported transaction?

After the reported sale, the Form 4 shows Mr. Berard beneficially owns 133,906 shares directly.

When was the Form 4 signed and filed for the BLFS transaction?

The Form 4 is signed by Todd Berard and dated 09/15/2025 reflecting the reported 09/11/2025 transaction.

Does the Form 4 report any derivative transactions or joint filings for this BLFS disclosure?

No. The filing lists a non-derivative sale and indicates the form was filed by one reporting person; no derivative securities or joint filers are reported.